Supriya Lifescience Gets Brazil's Nod For Mental Illness Drug
Supriya Lifescience Ltd. received approval for its mental illness drug Esketamine Hydrochloride from Brazil's health authority, 'Agência Nacional de Vigilância Sanitária', according to an exchange filing on Monday.
Esketamine Hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the Latin America market, the filing stated.
This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing, it added.
Supriya Lifescience added that it was the first company to receive approval from Brazil for Esketamine Hydrochloride.
"Our global presence is strengthened by the CADIFA (Brazil's letter of suitability for pharmaceutical products) approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil," said Satish Wagh, the executive chairman and director of Supriya Lifescience.
Atorvastatin Patent Filing
Supriya Lifescience also informed the exchanges that it has submitted "ground-breaking patent application" for an enhanced, and low-cost method of atorvastatin synthesis. Atorvastatin is a key treatment for controlling cholesterol and preventing cardiovascular disease, the company pointed out.
The drugmaker added that its ground-breaking technique makes medicines more affordable for patients by increasing their efficacy while reducing production costs.
"Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin," Wagh said.
Shares of Supriya Lifescience closed 1.28% higher at Rs 783.8 apiece on the NSE, compared to a 0.24% increase in the benchmark Nifty 50. The stock has risen by 149% on a year-to-date basis and by 190% over the past 12 months.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
